Q3 2025 Earnings Call Transcript November 4, 2025 Taysha Gene Therapies, Inc. misses on earnings expectations. Reported EPS ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

With greater understanding of the complex pathomechanisms of myalgic encephalomyelitis/chronic fatigue syndrome, researchers ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

In a pop-up city off the coast of Honduras, longevity startups are trying to fast-track anti-aging drugs. Is this the future ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

CAR T and CAR Treg therapies revolutionize cancer treatment through automation, scalability, and global manufacturing innovation.

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at ...

Intellia Therapeutics downgraded to Sell amid safety, regulatory setbacks and weak market prospects. Click here to read an ...

AI helps UCSD scientists destroy cancer stem cells, Nvidia tests data centres in space, and rival neutrino teams unite: ...

The post FDA Feedback Surprises Huntington’s Drug Watchers appeared first on Self Employed.